Literature DB >> 21590683

T cells stimulated with an analog peptide of type II collagen require the Fc receptor γ-chain to secrete interleukin-4 and suppress autoimmune arthritis in mice.

Linda K Myers1, David L Cullins, David D Brand, Sandra Kleinau, John M Stuart, Andrew H Kang.   

Abstract

OBJECTIVE: To explore the characteristics of the T cell population that responds to an analog peptide (A9) of type II collagen and regulates autoimmunity, using the collagen-induced arthritis (CIA) model.
METHODS: Analog peptide A9 is a 26-amino acid peptide analogous to the sequence of a segment of type II collagen (CII245-270) but with substitutions at amino acid positions 260 (alanine for isoleucine), 261 (hydroxyproline for alanine), and 263 (asparagine for phenylalanine). We previously showed that A9 profoundly suppressed CIA and immune responses to type II collagen. In order to determine the mechanism of suppression, we used transgenic mice whose T cells express a type II collagen-specific receptor (T cell receptor) and performed passive cell transfer experiments.
RESULTS: The results demonstrated that suppression of CIA by A9 is dependent on T cells. Using multiparameter flow cytometry, we determined that the cells responsible for suppression were CD4+ and expressed high levels of Fcε receptor Iγ chain (FcRγ). To establish the significance of this finding, we obtained mice genetically deficient in FcRγ in order to perform passive transfer experiments. The resulting FcRγ-/- CD4+ T cells, when primed by culture with A9, could not transfer the suppression of arthritis or secrete cytokines in response to A9.
CONCLUSION: Taken together, the results of this study suggest that the suppression of arthritis and the Th2 cytokine profile elicited by A9 is dependent on the presence of FcRγ in T cells. These findings are novel and may have therapeutic potential for patients with autoimmune arthritis.
Copyright © 2011 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21590683      PMCID: PMC3575180          DOI: 10.1002/art.30454

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  33 in total

Review 1.  Antigen-specific immunomodulation via altered peptide ligands.

Authors:  B Bielekova; R Martin
Journal:  J Mol Med (Berl)       Date:  2001-10       Impact factor: 4.599

2.  Detection of early changes in autoimmune T cell phenotype and function following intravenous administration of type II collagen in a TCR-transgenic model.

Authors:  David D Brand; Linda K Myers; Karen B Whittington; Kary A Latham; John M Stuart; Andrew H Kang; Edward F Rosloniec
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

3.  The role of IL-4 in regulation of murine collagen-induced arthritis.

Authors:  L K Myers; B Tang; J M Stuart; A H Kang
Journal:  Clin Immunol       Date:  2002-02       Impact factor: 3.969

4.  Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4.

Authors:  S H Kim; S Kim; C H Evans; S C Ghivizzani; T Oligino; P D Robbins
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

5.  Collagen-induced arthritis.

Authors:  Edward F Rosloniec; Michael Cremer; Andrew H Kang; Linda K Myers; David D Brand
Journal:  Curr Protoc Immunol       Date:  2010-04

6.  Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types.

Authors:  L Dumoutier; C Leemans; D Lejeune; S V Kotenko; J C Renauld
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

7.  Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.

Authors:  L Kappos; G Comi; H Panitch; J Oger; J Antel; P Conlon; L Steinman
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

8.  Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand.

Authors:  H J Kim; J P Antel; P Duquette; D G Alleva; P J Conlon; A Bar-Or
Journal:  Clin Immunol       Date:  2002-08       Impact factor: 3.969

9.  Induction and suppression of collagen-induced arthritis is dependent on distinct fcgamma receptors.

Authors:  S Kleinau; P Martinsson; B Heyman
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

10.  Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.

Authors:  L A Joosten; E Lubberts; M M Helsen; T Saxne; C J Coenen-de Roo ; D Heinegård; W B van den Berg
Journal:  Arthritis Res       Date:  1999-10-26
View more
  4 in total

1.  Peptide ligand structure and I-Aq binding avidity influence T cell signaling pathway utilization.

Authors:  Linda K Myers; David L Cullins; Jeoung-Eun Park; Ae-Kyung Yi; David D Brand; Edward F Rosloniec; John M Stuart; Andrew H Kang
Journal:  Clin Immunol       Date:  2015-05-14       Impact factor: 3.969

2.  Characterization of T cell phenotype and function in a double transgenic (collagen-specific TCR/HLA-DR1) humanized model of arthritis.

Authors:  Bo Tang; Seunghyun Kim; Sarah Hammond; David L Cullins; David D Brand; Edward F Rosloniec; John M Stuart; Arnold E Postlethwaite; Andrew H Kang; Linda K Myers
Journal:  Arthritis Res Ther       Date:  2014-01-10       Impact factor: 5.156

Review 3.  Peptide-Based Vaccination Therapy for Rheumatic Diseases.

Authors:  Bin Wang; Shiju Chen; Qing Zheng; Yuan Liu; Guixiu Shi
Journal:  J Immunol Res       Date:  2020-03-18       Impact factor: 4.818

4.  Characterization of inhibitory T cells induced by an analog of type II collagen in an HLA-DR1 humanized mouse model of autoimmune arthritis.

Authors:  Masaru Kimata; David L Cullins; Monica L Brown; David D Brand; Edward F Rosloniec; Linda K Myers; John M Stuart; Andrew H Kang
Journal:  Arthritis Res Ther       Date:  2012-05-08       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.